Net loss of Concord Drugs reported to Rs 0.34 crore in the quarter ended March 2024 as against net profit of Rs 0.16 crore during the previous quarter ended March 2023. Sales rose 27.05% to Rs 15.64 crore in the quarter ended March 2024 as against Rs 12.31 crore during the previous quarter ended March 2023.For the full year,net profit declined 52.53% to Rs 0.47 crore in the year ended March 2024 as against Rs 0.99 crore during the previous year ended March 2023. Sales declined 13.75% to Rs 44.92 crore in the year ended March 2024 as against Rs 52.08 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales15.6412.31 27 44.9252.08 -14 OPM %2.247.88 -9.028.79 - PBDT-0.150.47 PL 2.182.87 -24 PBT-0.550.14 PL 0.631.25 -50 NP-0.340.16 PL 0.470.99 -53 Powered by Capital Market - Live News

Concord Drugs has postponed the meeting of the Board of Directors which was scheduled to be held on 25 May 2024. The meeting will now be held on 30 May 2024.Powered by Capital Market - Live News

Concord Drugs will hold a meeting of the Board of Directors of the Company on 25 May 2024Powered by Capital Market - Live News

Net loss of Concord Drugs reported to Rs 0.24 crore in the quarter ended December 2023 as against net profit of Rs 0.45 crore during the previous quarter ended December 2022. Sales declined 5.54% to Rs 12.78 crore in the quarter ended December 2023 as against Rs 13.53 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales12.7813.53 -6 OPM %4.9310.64 - PBDT0.131.00 -87 PBT-0.260.62 PL NP-0.240.45 PL Powered by Capital Market - Live News

Concord Drugs will hold a meeting of the Board of Directors of the Company on 13 February 2024.Powered by Capital Market - Live News